Product Description: Spesolimab (BI 655130) is an anti-IL-36R antibody. IL-36 involves in immune system, as Spesolimab can be used for palmoplantar pustulosis (PPP) research. Spesolimab is associated with the reduction of biomarkers linked to innate, Th1/Th17, and neutrophilic pathways[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Mrowietz U, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585. /[2]Geller S, et al. CCR4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders and its implications for diagnosis and treatment[C]//Journal of Investigative Dermatology. STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC, 2019, 139(9): B25-B25.
CAS Number: 2097104-58-8
Molecular Weight: N/A
Compound Purity: 99.10
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Interleukin Related
English
Deutsch
